GT BiopharmaGTBP

13F holders, Q4 2024 (December 31)
18holders +2
3new positions
2sold out
$23.53avg. 13F price*

At the end of Q4 2024, 18 institutions reported holding GT Biopharma Inc. (GTBP) in their 13F filings, up 2 from Q3 2024. 3 opened new positions and 2 sold out. The largest holders were DekaBank Deutsche Girozentrale ($29.0M), Bank of Montreal ($88K) and Geode Capital Management, LLC ($45K).

Company
GT Biopharma Inc.
CUSIP
36254L308
Latest filing quarter
Q2 2026

History

Number of 13F holders

0204060 Q1 2024: 16Q1 2024Q2 2024: 17Q2 2024Q3 2024: 16Q3 2024Q4 2024: 18Q4 2024Q1 2025: 20Q1 2025Q2 2025: 21Q2 2025Q3 2025: 21Q3 2025Q4 2025: 38Q4 2025Q1 2026: 42Q1 2026Q2 2026: 59Q2 2026

Total Exit/New Position Q3 2024 → Q4 2024

InstitutionsTotal Value
New Positions3$5K
Exits2$23K

All 13F filers, Q3 2024 → Q4 2024: 10,025 shares bought and 11,173 shares sold, net −1,148 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.

Ownership 18 holders

DekaBank Deutsche Girozentrale 0.05% No change 1,154,867 $29.0M
Bank of Montreal 0.00% Reduce -3.1% 28,951 $88K
Geode Capital Management, LLC 0.00% Reduce -0.9% 14,899 $45K
Vanguard Group Inc. 0.00% No change 10,504 $32K
Wells Fargo & Company 0.00% No change 10,013 $31K
BlackRock, Inc. 0.00% No change 9,737 $30K
UBS Group AG 0.00% Add +28.0% 4,996 $15K
Morgan Stanley 0.00% Add +1228.2% 3,533 $11K
Tower Research Capital LLC (TRC) 0.00% Add +77.5% 2,917 $9K
Osaic Holdings, Inc. 0.00% Add +21941.7% 2,645 $8K
NFSG Corp 0.00% New 1,750 $5K
Bank of America Corp. 0.00% No change 27 $82
SBI Securities Co., Ltd. 0.00% — 16 $49
Blue Bell Private Wealth Management, LLC 0.00% No change 10 $31
BNP Paribas Financial Markets 0.00% No change 6 $18
Farther Finance Advisors, LLC 0.00% New 6 $18
Allworth Financial LP 0.00% New 2 $5
JPMorgan Chase & Co. 0.00% No change 1 $3

"% of holder's portfolio" is GTBP's weight in each manager's 13F, not the share of GT Biopharma Inc. the manager owns.